Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethylparaben (also known as ethyl hydroxybenzoate or E214) is a paraben-class compound widely used as an antimicrobial preservative in pharmaceuticals, cosmetics, and food products. It is the ethyl ester of p-hydroxybenzoic acid and acts by inhibiting the growth of fungi and bacteria through disruption of microbial cell membranes and inhibition of key enzyme systems. Ethylparaben is rapidly absorbed via the gastrointestinal tract or skin and metabolized to p-hydroxybenzoic acid before excretion. It has a broad spectrum of activity against molds, yeasts, and bacteria over a wide pH range (pH 4–8). There are concerns about its weak estrogenic activity at high exposure levels[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethylparaben.